The scale of the problem is considerable. Recent prescribing trend analyses in the United States show that anxiolytic, sedative, and hypnotic drugs remain widely dispensed, with benzodiazepine receptor agonists still among the most commonly used sleep aids despite decades of warnings. Clinical practice guidelines, including the American Academy of Sleep Medicine’s guideline on behavioral and psychological treatments for chronic insomnia, recommend cognitive behavioral therapy as the first-line treatment, yet medication use persists. In 2025, a joint clinical practice guideline on benzodiazepine tapering was published in the Journal of General Internal Medicine, offering clinicians a structured framework for when the risks of continued use outweigh the benefits. The guideline reflects a growing consensus that deprescribing should be a routine part of care, not an afterthought.

Deprescribing, however, is easier said than done. A systematic review and meta-analysis published in the BMJ in 2025 examined the comparative effectiveness of interventions designed to facilitate deprescription of benzodiazepines and other sedative hypnotics. The findings confirmed what many clinicians know from experience: simply advising patients to stop rarely works. Successful deprescribing typically requires gradual tapering schedules, psychological support, and sometimes substitution with an alternative medication that carries a lower risk of dependence. Even with structured programs, relapse and rebound insomnia remain common, and many patients abandon their taper attempts when sleep deteriorates.

This is where DORAs enter the picture. Unlike benzodiazepines, which enhance inhibitory signaling through GABA receptors and broadly suppress brain activity, DORAs such as suvorexant and lemborexant work through an entirely different mechanism. They block the action of orexin, also known as hypocretin, a neuropeptide system that promotes wakefulness. Orexin neurons in the hypothalamus act as a switch that stabilizes wakefulness; blocking orexin signaling reduces wake drive rather than sedating the brain outright. This flip-switch biology, first elucidated in studies of sleep-to-wake transitions, means DORAs promote sleep by quieting arousal systems rather than by forcing the brain into sedation, a distinction that may translate into fewer dependence-related concerns.

The safety profile of DORAs has been tested over longer horizons than many older hypnotics. A phase 3 randomized, double-blind, placebo-controlled trial published in Lancet Neurology in 2014 evaluated suvorexant over one year of treatment, followed by abrupt discontinuation. The study provided evidence that the drug could be used long term and, notably, that stopping it abruptly did not produce the severe withdrawal phenomena characteristic of benzodiazepine cessation. This absence of a pronounced withdrawal syndrome is precisely the property that makes DORAs attractive as candidates for assisting deprescribing: patients switching off benzodiazepine receptor agonists might maintain sleep continuity during the transition without acquiring a new dependence.

Several clinical studies have now put this idea to the test, and much of the evidence comes from Japan, where lemborexant has been widely adopted. A retrospective clinical practice study compared the usefulness of dual orexin receptor antagonists with a melatonin receptor agonist in patients switching from long-term benzodiazepine receptor agonists, finding the DORA approach promising for maintaining sleep during the switch. An open-label, multicenter study examined the efficacy and safety of transitioning Japanese patients with insomnia from Z-drugs, suvorexant, and ramelteon to lemborexant, adding further real-world data on how such switches play out in practice. Another study, the SLIM trial, focused specifically on patients with insomnia comorbid with mental disorders, a population in which benzodiazepine use is especially entrenched and deprescribing especially challenging.

Perhaps the most directly relevant new evidence comes from a mirror-image analysis of insurance claims data published in the Journal of Clinical Sleep Medicine in 2026. In a mirror-image design, researchers compare a period before an intervention with a corresponding period after it in the same patients, using each individual as their own control. The study examined dual orexin receptor antagonist-assisted dose reduction of benzodiazepines and benzodiazepine receptor agonists, asking whether starting a DORA helped patients actually reduce their doses of the older hypnotics. Complementing this, a nationwide claims database study in Japan evaluated prescribing patterns of switching to lemborexant or adding it on in patients already treated with hypnotic medication, mapping how clinicians are deploying the drug in real-world settings.

Reading this evidence together, Kolla and Mansukhani see genuine promise but also important caveats. The observational nature of most of the studies means that confounding cannot be excluded: patients who switch to DORAs may be more motivated to deprescribe in the first place, and claims data capture prescriptions rather than actual ingestion or sleep outcomes. Mirror-image analyses, while clever, cannot fully substitute for randomized controlled trials in which patients on long-term benzodiazepine receptor agonists are randomly assigned to DORA-assisted tapering versus tapering alone or placebo. Until such trials are completed, the question posed in the commentary’s title remains formally open, even if the direction of the evidence is encouraging.

There are also practical considerations for clinicians contemplating a switch. DORAs carry their own side effects, most notably next-day somnolence and, for suvorexant, complex sleep behaviors that prompted regulatory warnings. Cost and access vary across health systems, and DORAs are considerably more expensive than generic Z-drugs in many countries. Tapering benzodiazepines still requires patience, with reductions often spaced over weeks or months, and behavioral treatment for insomnia should ideally run in parallel, since medication switching alone does not address the underlying sleep-disrupting beliefs and habits that sustain chronic insomnia. The deprescribing guideline emphasizes that tapering should be individualized, and a DORA may serve as a bridge rather than a destination.

What makes this line of research compelling is that it reframes deprescribing from an act of subtraction into one of substitution. Instead of asking patients to give up sleep they feel they cannot function without, clinicians can offer a pharmacological alternative with a fundamentally different mechanism and a more favorable long-term safety profile. The commentary by Kolla and Mansukhani synthesizes the accumulating Japanese clinical experience and the emerging claims-based analyses into a coherent argument that DORAs deserve a place in deprescribing strategies, while candidly acknowledging the need for rigorous randomized evidence. For the millions of patients caught in long-term use of benzodiazepine hypnotics and Z-drugs, the orexin system’s wake-promoting switch may prove to be the off-ramp that older sedatives never offered, but confirming that promise will require the controlled trials that the field has yet to deliver.

Subject of Research: Use of dual orexin receptor antagonists to facilitate deprescribing of benzodiazepine hypnotics and Z-drugs in insomnia

Article Title: Deprescribing benzodiazepine hypnotics and Z-drugs: are DORAs the answer?

Article References: Kolla, B. P., & Mansukhani, M. P. (2026). Deprescribing benzodiazepine hypnotics and Z-drugs: are DORAs the answer?. Journal of Clinical Sleep Medicine, 22(1), Article 188. https://doi.org/10.1007/s44470-026-00186-5

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00186-5

Keywords: benzodiazepines, Z-drugs, dual orexin receptor antagonists, deprescribing, insomnia, sleep medicine, lemborexant, suvorexant, orexin, tapering, pharmacology, Mayo Clinic

Chronotype, the technical term for an individual’s innate preference for morning or evening activity, is governed by the circadian system, the internal biological clock that orchestrates fluctuations in hormone secretion, core body temperature, alertness, and sleep propensity across the roughly twenty-four-hour day. Most people fall somewhere on a continuum between extreme morningness and extreme eveningness, and this preference is partly genetic, remarkably stable across adulthood, and measurable with validated self-report instruments such as the Horne and Östberg morningness-eveningness questionnaire, the very tool used in the new research. What makes chronotype clinically interesting is its repeated association with mental health: large population studies have linked evening orientation to elevated rates of depression and anxiety, and a growing body of work implicates circadian misalignment in the onset and persistence of psychiatric illness.

Veterans represent a population in which these questions carry unusual urgency. Military service imposes chronic circadian disruption through shift work, deployments, night operations, and irregular schedules, and veterans are known to experience more severe sleep difficulties than community-dwelling civilians who never served. At the same time, depression, post-traumatic stress disorder, and suicidality are markedly elevated in this group, and the Department of Veterans Affairs continues to track suicide prevention as a central clinical priority. Yet, as Ulmer and her colleagues note, relatively few studies have systematically examined chronotype in veterans, leaving a gap in understanding how biological sleep timing interacts with the psychological aftermath of military service.

To address that gap, the research team drew on a multi-site post-deployment health repository, the Post-Deployment Mental Health study and registry, which enrolls US veterans who served in the Afghanistan and Iraq eras. From this registry the investigators analyzed data from 144 veterans who had completed a battery of well-validated self-report measures. Chronotype was classified using the Horne and Östberg questionnaire, a classic instrument that asks respondents about their preferred wake times, bedtimes, and periods of peak alertness. Depression symptoms were assessed with the PHQ-8, post-traumatic stress symptoms with the PTSD Checklist for DSM-5, insomnia severity with the Insomnia Severity Index, general sleep quality with the Pittsburgh Sleep Quality Index, and trauma-associated sleep disturbance with the Pittsburgh Sleep Quality Index Addendum for PTSD, a scale designed to capture nightmares and nocturnal behaviors specific to trauma survivors.

The analytical approach was deliberately conservative. The researchers used analysis of covariance to compare symptom levels across chronotype groups while statistically adjusting for age and sex, two demographic factors that can independently influence both sleep timing and mental health. They also applied false discovery rate control, a modern statistical correction that guards against spurious findings when many comparisons are tested simultaneously, a rigor that strengthens confidence in the patterns that survived. This matters because chronotype research, like much of sleep science, has historically wrestled with small samples and inconsistent methodology, and the field has called for studies that can distinguish genuine associations from statistical noise.

The results were clear and, in several respects, sobering. Consistent with prior research in civilian and military samples, evening types endorsed substantially greater symptomatology across measures of depression and PTSD compared with morning types. The night owls in the sample also reported more severe insomnia symptoms and poorer overall sleep quality. Crucially, the team tested whether these relationships could be explained simply by veterans sleeping fewer hours, and they were not: the associations between evening chronotype and worse mental health and sleep outcomes held even after accounting for sleep duration. In other words, it is not merely that late-timing veterans sleep less; something about the timing and alignment of their biological rhythms itself appears tied to their symptom burden.

One finding, however, broke from expectation. Chronotype was not associated with trauma-associated sleep disturbance as measured by the PTSD-specific addendum scale. This dissociation is scientifically intriguing. It suggests that the nightmares, night sweats, and nocturnal hypervigilance that characterize trauma-related sleep disruption may follow a different pathophysiological logic than general insomnia and poor sleep quality, one less dependent on the underlying circadian preference. The authors also point to a broader literature, including a twin study suggesting quasi-causal associations between chronotype and PTSD symptoms and an individual participant data meta-analysis linking sleep timing to post-traumatic stress, indicating that the chronotype-PTSD relationship remains an active and contested area of investigation.

Why might eveningness carry this psychiatric burden? Several mechanisms have been proposed in the wider literature. Living against the grain of one’s internal clock, a phenomenon researchers call social jetlag, forces evening types to wake for work, school, or family obligations before their biology is ready, producing chronic circadian misalignment that has been linked to inflammation, metabolic dysregulation, and impaired emotional brain circuits. Evening types also face greater exposure to darkness and social isolation during their peak waking hours, potentially compounding low mood. Disrupted circadian rhythms have been shown in translational studies to affect neurotransmitter systems, stress hormone regulation, and the architecture of REM sleep, the sleep stage most implicated in emotional memory processing and trauma-related nightmares. None of these mechanisms was directly tested in the veteran study, but they offer a plausible framework for why a late body clock and heavy psychiatric symptoms travel together.

The clinical implications are where the study’s authors place their strongest emphasis. They argue that consideration of chronotype may be important for case conceptualization in military veterans, particularly those presenting with elevated depression, suicidality, or trauma-related symptoms. In practical terms, a clinician who knows that a veteran is a pronounced evening type gains a piece of risk information that costs nothing to collect and may help identify phenotypes at increased risk of greater psychiatric symptom burden. The finding also speaks directly to treatment. Cognitive behavioral therapy for insomnia, the first-line, guideline-recommended treatment for chronic insomnia, includes components that deliberately shift sleep timing, and prior research has shown that shifts toward morningness during such interventions are associated with improvements in depression, positive affect, and sleep quality. Chronotype has also been found to moderate outcomes in digital and group-based CBT-I programs, meaning that a veteran’s circadian preference could influence how well standard sleep treatments work for them.

The study’s limitations temper but do not diminish its message. With 144 participants, the sample is modest, and the cross-sectional design means the data cannot establish whether eveningness predisposes veterans to worse symptoms, whether psychiatric illness pushes people toward later schedules, or whether both are driven by shared underlying factors. Self-reported measures, however well validated, capture perception rather than objective circadian physiology, and the registry sample may not represent all veteran populations. Still, the convergence of this veteran data with a large international literature on chronotype and mental health makes a compelling case that the question deserves a permanent place in clinical assessment. For the millions of veterans navigating the invisible injuries of service, the humble body clock, long treated as a matter of personal habit, is emerging as a measurable biological variable with real consequences for mental health, and one that clinicians can begin acting on today.

Subject of Research: Associations between chronotype and symptoms of depression, PTSD, and sleep disturbances in US military veterans

Article Title: An examination of chronotype associations with symptoms of depression, PTSD, and sleep disturbances in US military veterans

Article References: Ulmer, C. S., Wilson, S. C., Ysidron, D., & Ferguson, S. (2026). An examination of chronotype associations with symptoms of depression, PTSD, and sleep disturbances in US military veterans. Journal of Clinical Sleep Medicine, 22(1), Article 183. https://doi.org/10.1007/s44470-026-00165-w

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00165-w

Keywords: chronotype, military veterans, depression, PTSD, insomnia, sleep quality, circadian rhythms, eveningness, cognitive behavioral therapy for insomnia, sleep timing, mental health, post-deployment health

The commentary accompanies a large epidemiological analysis drawn from TURKAPNE, a nationwide Turkish sleep apnea cohort, which found that diabetes mellitus is associated with both an increased prevalence and an increased severity of COMISA. That finding matters because COMISA is not a rare curiosity. Studies of sleep clinic populations and community cohorts suggest that a substantial share of patients diagnosed with obstructive sleep apnea also report chronic insomnia symptoms, and vice versa, yet the overlap has historically been under-recognized. Patients with COMISA often fall through diagnostic cracks: their insomnia complaint may mask the apnea during a routine visit, or the apnea diagnosis may lead clinicians to dismiss the insomnia as secondary, leaving the underlying sleep fragmentation untreated.

Part of what makes COMISA biologically plausible as a driver of metabolic disease is the distinct sleep architecture it produces. Research comparing patients with COMISA against those with obstructive sleep apnea alone or insomnia alone has shown that the combined disorder is associated with a unique pattern of sleep disruption, blending the repetitive upper airway collapses and oxygen desaturations of apnea with the prolonged sleep-onset difficulties and nocturnal awakenings characteristic of insomnia. In laboratory studies, acute intermittent hypoxia, the hallmark physiological insult of sleep apnea, has been shown to impair glucose metabolism even in awake, healthy volunteers, suggesting a direct mechanistic pathway from oxygen fluctuation to insulin resistance.

The insomnia component adds its own metabolic burden. A systematic review and meta-analysis focusing on insomnia disorder characterized by objectively short sleep duration found associations with hypertension, diabetes, and elevated body mass index. In other words, the subset of insomnia patients whose bodies cannot compensate for their sleep loss with longer time in bed appears to carry measurable cardiometabolic risk. When that short, fragmented sleep is layered on top of the cyclical hypoxemia of sleep apnea, the two insults may act synergistically on the sympathetic nervous system, the hypothalamic-pituitary-adrenal axis, and inflammatory pathways, all of which are central to glucose homeostasis.

Cardiovascular data reinforce the concern. An analysis of a large sleep registry found that type 2 diabetic patients with co-morbid insomnia and sleep apnea faced elevated cardiovascular risk compared with diabetic patients who had neither or only one of the two sleep disorders. Separately, work on the so-called hypoxic burden, a quantitative measure of the oxygen desaturation load carried during sleep, has shown that this metric predicts cardiovascular disease-related mortality better than the traditional apnea-hypopnea index in large community cohorts such as the Osteoporotic Fractures in Men Study and the Sleep Heart Health Study. Sankari’s own longitudinal research on nocturnal heart rate variability, measured through R-R interval changes in a community-based cohort, has similarly pointed to autonomic dysregulation during sleep as a harbinger of adverse cardiovascular outcomes.

What the TURKAPNE findings add is epidemiological weight to the idea that the arrow may point in both directions. Diabetes is associated with more prevalent and more severe COMISA, but the mechanistic literature suggests COMISA may also worsen glycemic control, creating a potential feedback loop. Hyperglycemia can promote nocturia, neuropathic pain, and restless discomfort that fragment sleep, while fragmented, hypoxic sleep promotes insulin resistance, appetite dysregulation through altered leptin and ghrelin signaling, and weight gain, which in turn worsens both apnea severity and metabolic control. Breaking this loop, the commentary argues, requires treating the two sleep disorders together rather than sequentially.

Treatment evidence is beginning to catch up with the biology. The most striking recent development comes from trials of tirzepatide, a dual incretin agonist originally developed for diabetes and obesity, which demonstrated significant reductions in the apnea-hypopnea index in patients with obstructive sleep apnea and obesity. Meta-analytic work on weight reduction more broadly confirms that even modest weight loss produces meaningful drops in apnea severity. For patients with COMISA and type 2 diabetes, these agents occupy a uniquely attractive position, because they simultaneously target the metabolic disease, the body weight that drives airway collapse, and potentially the sleep-disordered breathing that feeds back into glycemic instability. Whether they also ameliorate the insomnia component of COMISA remains an open question that researchers are only beginning to explore.

The pharmacological picture is complicated by safety concerns on the insomnia side. Longitudinal primary care data have linked prescriptions of hypnotics and anxiolytics with increased mortality, particularly in multimorbid patients, a category that describes many older adults with type 2 diabetes and coexisting sleep disorders. This makes non-pharmacological approaches, above all cognitive behavioral therapy for insomnia, the preferred first-line option for the insomnia component, while positive airway pressure therapy remains the cornerstone of apnea treatment. The challenge, as the commentary emphasizes, is that adherence to positive airway pressure is notoriously poor among patients with comorbid insomnia, who may find the mask and airflow intolerable when they already struggle to fall asleep. Integrated treatment pathways that address both disorders from the outset, rather than treating apnea first and hoping insomnia resolves, may improve adherence and outcomes for both.

Screening represents another frontier. Obstructive sleep apnea in women, particularly around reproductive aging and menopause, is frequently missed because presenting complaints differ from the classic male phenotype of loud snoring and witnessed apneas, and insomnia symptoms can further obscure the picture. Sankari and colleagues have highlighted these screening challenges in recent work, and the same logic applies to diabetic patients of both sexes: a patient who reports difficulty falling or staying asleep should prompt clinicians to consider whether sleep-disordered breathing is hiding underneath, and a patient prescribed continuous positive airway pressure who remains fatigued should be evaluated for persistent insomnia. Simple validated screening instruments for both conditions could be deployed in endocrinology and primary care clinics at minimal cost.

The commentary’s central message is ultimately one of reframing. Coexistence is not the right word for what happens when diabetes, insomnia, and sleep apnea converge in a single patient; the evidence points toward genuine pathophysiological entanglement, with each condition amplifying the others through hypoxic stress, autonomic activation, inflammatory signaling, and behavioral pathways such as sedentary fatigue and disordered eating. Large prospective cohorts that track sleep architecture, hypoxic burden, and glycemic outcomes simultaneously will be needed to establish causality and to determine whether treating COMISA aggressively improves diabetes complications and cardiovascular survival. Until then, the practical takeaway for clinicians is clear: in a patient with type 2 diabetes who sleeps badly, neither the insomnia nor the apnea should be treated as background noise, because together they may be quietly driving the disease that brought the patient to the clinic in the first place.

Subject of Research: The bidirectional relationship between type 2 diabetes and comorbid insomnia and sleep apnea (COMISA)

Article Title: Beyond coexistence: attempting to unlock the diabetes–COMISA Link

Article References: Sankari, A. (2026). Beyond coexistence: attempting to unlock the diabetes–COMISA link. Journal of Clinical Sleep Medicine, 22(1), Article 125. https://doi.org/10.1007/s44470-026-00135-2

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00135-2

Keywords: COMISA, type 2 diabetes, obstructive sleep apnea, insomnia, sleep medicine, intermittent hypoxia, glucose metabolism, cardiovascular risk, TURKAPNE cohort, tirzepatide, cognitive behavioral therapy for insomnia, sleep architecture

The research team, led by Douglas Barroso of the State University of Santa Cruz in Brazil together with co-senior authors Daniel B. Kay of Brigham Young University and Renatha El Rafihi-Ferreira of the University of São Paulo, set out to answer a question that has grown increasingly urgent as insomnia rates climb worldwide. Insomnia disorder, defined by persistent difficulty falling or staying asleep despite adequate opportunity for sleep, affects a substantial proportion of adults across cultures and carries enormous societal costs, from lost productivity to elevated risks of depression and even suicidal behavior. Previous epidemiological surveys in England documented rising insomnia prevalence and increased use of hypnotic medications over fifteen years, underscoring the need for effective, accessible, non-pharmacological treatments.

CBT-I has long been the first-line recommendation in clinical guidelines from the American Academy of Sleep Medicine and the European Sleep Research Society. Its efficacy is well established across dozens of trials and multiple meta-analyses, including studies showing benefits even when insomnia is comorbid with psychiatric and medical conditions or chronic disease. Yet CBT-I has a practical weakness: its core behavioral components, particularly sleep restriction therapy, which deliberately compresses time in bed to rebuild sleep drive, can be demanding and uncomfortable for patients. Research on patient experience has shown that adherence to sleep restriction is a genuine barrier, and studies of treatment-seeking behavior reveal that many people with insomnia never pursue therapy at all. This is where ACT enters the picture with a fundamentally different philosophy.

Acceptance and commitment therapy, developed from the framework of contextual behavioral science, does not attempt to eliminate unwanted thoughts or sensations directly. Instead, it targets experiential avoidance, the struggle to control or escape difficult inner experiences, and cultivates psychological flexibility through acceptance, mindfulness, values clarification, and committed action. Applied to insomnia, ACT encourages patients to stop waging war against wakefulness. Rather than lying in bed monitoring the clock and catastrophizing about tomorrow, patients learn to observe sleep-related thoughts without acting on them and to redirect energy toward what matters in their lives regardless of how a given night unfolds. A influential metacognitive model of insomnia published by Ong, Ulmer, and Manber in 2012 provided the theoretical foundation for this approach, arguing that the effortful struggle to sleep is itself a maintaining factor of the disorder.

To test how well this philosophy translates into clinical outcomes, the researchers conducted a systematic review and meta-analysis following Cochrane Handbook guidance and PRISMA 2020 reporting standards, assessing risk of bias in included trials with the revised RoB 2 tool. They searched three major databases for randomized controlled trials comparing ACT or ACT-based interventions against non-ACT conditions in patients with insomnia. Continuous outcomes were pooled using a restricted maximum likelihood random-effects model in the statistical environment R, a method that accounts for heterogeneity between studies while producing robust combined estimates. The trials encompassed a range of delivery formats, including face-to-face individual and group therapy, telehealth programs enhanced with ACT principles, and internet-delivered self-help interventions for subclinical and clinical insomnia.

The headline result was unambiguous. Compared with waitlist or standard control conditions, ACT produced a standardized mean difference of minus 0.67 in insomnia symptom severity, with a 95 percent confidence interval of minus 1.08 to minus 0.25, a moderate-to-large effect by conventional statistical conventions. In practical terms, patients receiving ACT reported substantially reduced insomnia severity on validated instruments such as the Insomnia Severity Index. Perhaps even more striking were the effects on psychological wellbeing: ACT yielded a small-to-moderate reduction in depression symptoms, with a standardized mean difference of minus 0.34, and a comparable reduction in anxiety symptoms, at minus 0.42, both statistically significant. These secondary outcomes matter enormously, because insomnia and mood disorders are deeply intertwined, with longitudinal evidence suggesting primary insomnia is a risk factor for developing depression.

The direct comparison with CBT-I told a more nuanced story. At posttreatment, there was no significant difference in insomnia severity between the two therapies, with a standardized mean difference of 0.21 favoring CBT-I but with a confidence interval of minus 0.02 to 0.43 that crossed the null. At six-month follow-up the gap narrowed further to a non-significant 0.14. Treatment response rates, defined as a reduction of more than seven points on the Insomnia Severity Index, also did not differ significantly between the therapies. However, one metric did separate them: CBT-I produced significantly higher remission rates at posttreatment, defined as an Insomnia Severity Index score below 8, with a relative risk of 0.81 for ACT, meaning ACT patients were somewhat less likely to achieve full remission by that strict threshold. By follow-up, even this advantage had dissolved into statistical equivalence, with a relative risk of 0.78 and a wide confidence interval of 0.47 to 1.29.

The authors interpret these findings with careful balance. ACT, they conclude, can be an efficacious treatment for insomnia, with particularly strong outcomes for the psychological symptoms that so often accompany sleepless nights. Nevertheless, CBT-I remains the gold standard due to its more extensive and consistent evidence base. This distinction between efficacy and evidentiary maturity is crucial for clinicians and policymakers. CBT-I has accumulated decades of trial data, dose-response evidence showing that more sessions yield better outcomes, and demonstrated effectiveness across primary care settings, group formats, telephone consultations, and digital platforms. ACT for insomnia, by contrast, rests on a smaller but rapidly growing foundation, including recent head-to-head randomized trials in chronic insomnia patients, comparative effectiveness research in women veterans, and pilot studies combining ACT with bedtime restriction.

The implications for clinical practice are nonetheless significant. If ACT matches CBT-I on symptom severity and outperforms it on durability of remission advantage over time, while additionally delivering meaningful relief from depression and anxiety, it offers clinicians a genuine choice in tailoring treatment. Patients who find the demanding behavioral prescriptions of CBT-I unpalatable, or who present with prominent comorbid mood symptoms, may be better suited to an acceptance-based approach. The growing menu of ACT delivery formats, from internet-based self-help to telehealth, also speaks to the pressing problem of treatment access, since most people with insomnia never receive any evidence-based psychological care. As the field moves toward personalized sleep medicine, this updated meta-analysis provides the strongest evidence yet that teaching patients to accept the night, rather than conquer it, is a scientifically legitimate path to better sleep.

Subject of Research: Efficacy of acceptance and commitment therapy compared with cognitive behavioral therapy for insomnia

Article Title: Acceptance and commitment therapy for insomnia: an updated meta-analysis of randomized controlled trials

Article References: Barroso, D., de Paula Portilho, N., Garbacka-Struzik, A., Godoi, D. C., Ellwanger, M. P., Pereira Mendes, T., Alves Ribeiro, V. E., Soares, V. G., Hespanhol, L. C., Siegloch, M. L., Zahran, I. R., Stadler de Abreu, V., de Oliveira, H. M., Peluffo, B., Cerchi, E., Kay, D. B., & Rafihi-Ferreira, R. E. (2026). Acceptance and commitment therapy for insomnia: an updated meta-analysis of randomized controlled trials. Journal of Clinical Sleep Medicine, 22(1), Article 132. https://doi.org/10.1007/s44470-026-00125-4

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00125-4

Keywords: acceptance and commitment therapy, ACT, insomnia, CBT-I, cognitive behavioral therapy, meta-analysis, randomized controlled trials, sleep medicine, psychological flexibility, depression, anxiety, Journal of Clinical Sleep Medicine

The target of the letter, a study by Ahmadi and colleagues, took advantage of a randomized clinical trial to ask a deceptively simple question. When older adults undergo CBT-I and their sleep improves, does the electrical signature of their deep sleep change as well, and do those changes move in lockstep with improvements in memory performance? Slow-wave activity, the high-amplitude, low-frequency oscillations that dominate the electroencephalogram during the deepest stages of non-rapid eye movement sleep, has long been implicated in memory consolidation. The idea that restoring more robust slow waves in people with insomnia could restore some of the memory difficulties that accompany poor sleep is an attractive one, and testing it in a controlled trial setting represents an important step beyond cross-sectional surveys that can only show correlations at a single point in time.

The theoretical backdrop here is decades of work on sleep-dependent memory consolidation. During slow-wave sleep, the hippocampus, which acts as a fast, temporary store for newly learned information, is thought to replay recent memories in compressed bursts. These replays are coordinated with cortical slow oscillations, thalamic spindles, and hippocampal ripples, forming a nested hierarchy of rhythms that gradually redistributes labile memories into long-term cortical networks. In this framework, the depth and intensity of slow-wave activity serve as a kind of gauge of the brain’s overnight memory-processing capacity. Older adults typically show reduced slow-wave amplitude, and this reduction has been repeatedly associated with weaker overnight memory retention, which helps explain why the prospect of reversing it through insomnia treatment has generated so much interest.

CBT-I itself is the first-line treatment for chronic insomnia, recommended ahead of medication by clinical guidelines across the world. Rather than acting on brain chemistry directly, it works through behavioral and cognitive levers: stimulus control re-associates the bed with sleep rather than wakefulness and worry, sleep restriction consolidates fragmented nights into a denser block of sleep, and cognitive restructuring defuses the anxious beliefs about sleeplessness that keep the disorder alive. Systematic reviews and meta-analyses, including a 2024 component network meta-analysis by Furukawa and colleagues published in JAMA Psychiatry, have mapped which components and delivery formats work best in adults, and separate reviews have documented benefits in working populations. What has been less clear is whether the therapy’s effects reach beyond sleep itself, into the cognitive machinery that sleep is supposed to support.

This is precisely the territory that Zhang and Guo’s letter probes. A letter to the editor in a clinical journal typically does not present new data; instead, it scrutinizes the interpretation of published findings, and that interpretive role matters enormously for how results ripple outward into clinical practice and popular understanding. When a secondary analysis reports an association between slow-wave activity changes and memory improvement after CBT-I, the natural headline that follows is that better deep sleep drives better memory. The letter’s title, Reconsidering the sleep–memory link after insomnia therapy in older adults, signals that the authors believe the causal story may be more complicated, and that the field should resist collapsing a nuanced pattern of evidence into a simple before-and-after narrative.

There are good technical reasons for such caution. In a secondary analysis, the measures of interest were not necessarily chosen or timed with the sleep-memory question in mind, and the statistical power to detect a genuine brain-behavior association may differ substantially from the power needed to detect the trial’s primary treatment effect. Slow-wave activity is also notoriously variable, both within a single night and between nights, so a single laboratory recording before and after treatment may capture only a noisy snapshot of a person’s typical sleep architecture. Memory, meanwhile, is not a single faculty: episodic recall, working memory, and procedural skill can respond differently to sleep changes, and the specific tasks used in a trial shape which aspects of cognition are sensitive to improvement. Any of these factors can weaken or distort an observed correlation without invalidating the underlying science.

There is also the perennial problem of confounding in observational associations embedded within trials. If CBT-I reduces insomnia severity, depression, anxiety, or the sedating burden of hypnotic medications, all of these changes could plausibly improve memory test performance through routes that have nothing to do with slow waves. Conversely, slow-wave activity might increase simply because sleep becomes more consolidated and less fragmented, without any direct enhancement of the memory-consolidation machinery. In that scenario, slow-wave activity would function as a marker of improved sleep quality rather than as the mechanism by which memory improves, and interventions aimed specifically at boosting slow waves might then fail to deliver the cognitive benefits that patients and clinicians would expect. Distinguishing a biomarker from a mechanism is one of the hardest problems in sleep neuroscience, and it is exactly the kind of distinction that a well-aimed letter can force the field to confront.

None of this diminishes the value of the original investigation. Randomized clinical trials of CBT-I that collect overnight electroencephalography are rare and resource-intensive, and secondary analyses that mine them for mechanistic insight are a legitimate and often productive strategy. Work in other age groups underscores why the question is worth pursuing: studies of sleep electroencephalogram oscillations and memory processing during childhood and adolescence, such as the 2023 analysis by Kurz, Zinke, and Born in Developmental Psychology, show that the relationship between sleep rhythms and memory evolves across the lifespan, shaped by maturational processes that differ from those operating in aging brains. Findings from younger populations cannot simply be transplanted to older adults, whose slow waves are smaller, whose sleep is more fragile, and whose memory complaints may reflect heterogeneous underlying causes ranging from normal aging to early neurodegeneration.

The practical stakes are considerable. Millions of older adults live with chronic insomnia, and many of them also worry about memory. If treating insomnia reliably improved cognition, CBT-I would become not just a sleep therapy but a preventive intervention against age-related cognitive decline, a claim with enormous public health implications. But if the sleep-memory link after treatment is weaker, more conditional, or more indirect than early reports suggest, then overselling the cognitive benefits risks disappointment and misallocated expectations, even as the well-established benefits of CBT-I for sleep itself remain fully intact. Careful interpretive scrutiny, of the kind Zhang and Guo’s letter exemplifies, is therefore not a hostile act toward the original research but a necessary part of building an evidence base that can support confident clinical recommendations.

The episode also illustrates how science actually refines itself. A trial is run, a secondary analysis draws a mechanistic association, and colleagues elsewhere scrutinize the inference, prompting everyone to specify more precisely what the data do and do not show. The letter, published in Volume 22 of the Journal of Clinical Sleep Medicine with no declared competing interests and no external funding, joins a broader conversation that includes component-level meta-analyses of CBT-I and lifespan studies of sleep oscillations. The next steps that follow naturally from this exchange are larger trials with electroencephalography designed from the outset to test memory outcomes, repeated sleep recordings to average out night-to-night variability, and mediation analyses that can separate the effects of improved sleep quality from the specific contribution of slow-wave activity. Until those results arrive, the wisest reading is a measured one: CBT-I remains the gold standard for insomnia, deep sleep remains a compelling candidate mechanism for memory consolidation, and the precise thread connecting the two in older adults is still being carefully untangled.

Subject of Research: The relationship between slow-wave sleep changes after cognitive behavioral therapy for insomnia and memory function in older adults

Article Title: Reconsidering the sleep–memory link after insomnia therapy in older adults

Article References: Zhang, W., & Guo, X. (2026). Reconsidering the sleep–memory link after insomnia therapy in older adults. Journal of Clinical Sleep Medicine, 22(1), Article 137. https://doi.org/10.1007/s44470-026-00160-1

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00160-1

Keywords: insomnia, cognitive behavioral therapy for insomnia, slow-wave sleep, memory consolidation, older adults, sleep electroencephalography, randomized clinical trial, sleep-dependent memory, aging brain, sleep medicine, episodic memory, cognitive aging

To understand why this seemingly technical dispute matters, it helps to unpack what the criterion actually requires. Under the diagnostic frameworks used widely in clinical practice, insomnia disorder is defined by complaints of sleep quantity or quality accompanied by daytime impairment, occurring despite adequate opportunity for sleep. The opportunity clause is the linchpin of the whole construction. If a person lies in bed for eight hours and sleeps for five, that pattern is compatible with insomnia. If a person is woken repeatedly by an external cause — a blaring alarm, a crying infant, a noisy hospital ward — the same five hours of sleep is attributed to the circumstance rather than to an internal sleep disorder. The logic is sound in principle: it protects the diagnostic category from being diluted by situational sleep loss, which is expected to resolve when the situation changes. Insomnia, by contrast, is supposed to persist even when the opportunity to sleep is restored.

The problem, as Huang and Shen see it, is that the postpartum period breaks the clean separation between opportunity and ability on which this logic depends. A mother of a newborn does not lack sleep opportunity in the way a shift worker on a rotating roster might; she typically spends long stretches in bed, often more hours than before pregnancy, because she grabs rest whenever the baby sleeps. Yet her sleep is fragmented by infant feeding and caregiving demands that are unpredictable, distributed across the 24-hour day, and largely outside her control. Whether her fragmented sleep reflects a genuine vulnerability to insomnia, or merely the ambient disruption of caring for a newborn, cannot be determined by asking whether she had an adequate opportunity to sleep. On paper she did. In practice, the opportunity was riddled with interruptions. The criterion, the authors argue, therefore returns the same answer — opportunity was adequate — for two very different clinical populations, and in doing so it discriminates between neither of them.

The empirical backdrop for this argument comes from the prospective study the letter addresses. Takenoshita and colleagues followed women to six weeks after delivery and assessed insomnia disorder using standard diagnostic criteria, publishing their findings in the same journal under the title “Insomnia disorder at 6 weeks postpartum: a prospective study.” Six weeks postpartum is a clinically meaningful time point: it coincides with routine postnatal follow-up, and it is early enough that infant night waking remains intense for most families. If a substantial proportion of women meet full diagnostic criteria for insomnia disorder at that visit, the question immediately arises of how many of those diagnoses reflect a persistent internal sleep disorder rather than sleep disruption driven by infant care. The letter’s central claim is that the opportunity criterion, as currently operationalized, cannot answer that question — and that this failure is structural, not a matter of the threshold being set slightly too high or too low.

Support for this position comes from a second line of evidence the authors cite: a longitudinal study by Quin, Lee, Pinnington, Newman, Manber and Bei, published in the journal Sleep, which tracked women from pregnancy through two years postpartum with the explicit aim of differentiating perinatal insomnia disorder from sleep disruption. The very existence of such a study underscores how contested the boundary is. If the standard criteria cleanly separated the two conditions, a dedicated longitudinal effort to disentangle them would be unnecessary. The study’s design — repeated assessment across pregnancy and the first two years after birth, a window in which infant-related sleep disruption gradually recedes while vulnerability to insomnia may either persist or resolve — represents one of the most direct attempts to test whether the diagnostic boundary holds up under real perinatal conditions.

The scale of the population affected gives the debate public-health weight. A nationwide analysis by Sultan, Guo, Kawai, Barwick, Carvalho, Mackey and colleagues, published in the Journal of Maternal-Fetal and Neonatal Medicine, examined the prevalence and predictors of postpartum sleep disorders across a large population, confirming that sleep disorders after childbirth are common enough to constitute a significant burden on maternal health services. Postpartum sleep problems do not exist in a diagnostic vacuum. They are entangled with mood disorders — the Edinburgh Postnatal Depression Scale, developed by Cox, Holden and Sagovsky in 1987 and cited in the letter, remains the standard screening instrument for postnatal depression — and untreated insomnia in the postpartum period is associated with worse maternal mental health, impaired daytime functioning, and difficulties with infant care. A diagnostic criterion that cannot reliably separate disorder from disruption therefore has consequences that ripple through screening, treatment decisions, and the allocation of scarce perinatal mental-health resources.

The practical stakes become concrete when one considers what happens at the bedside. A clinician evaluating a woman six weeks after delivery who reports difficulty falling back asleep after night feedings, daytime exhaustion, and irritability must decide whether she has insomnia disorder requiring targeted treatment — such as cognitive behavioral therapy for insomnia, the recommended first-line intervention — or whether her symptoms are an expected response to infant care that will ease as the baby’s sleep consolidates. The opportunity criterion was supposed to guide this judgment, but in the postpartum context it offers little traction. Most new mothers can honestly report that they had time in bed; few can cleanly separate the contribution of a hyperaroused, insomnia-like physiology from the contribution of a baby who wakes every three hours. The result, Huang and Shen suggest, is a category that either over-includes, pathologizing normal parental sleep disruption, or under-includes, denying treatment to women whose insomnia vulnerability has been genuinely triggered by the postpartum period and will persist long after the infant sleeps through the night.

The letter’s phrasing — “non-discriminating, not merely too strict” — signals a deliberate intervention in how the field frames the problem. Critics of the opportunity criterion in perinatal populations have often described it as overly strict, implying that the fix is a relaxed threshold or a postpartum-specific exception. Huang and Shen reject that framing. If the criterion were merely too strict, it would still point in the right direction, just with an unhelpfully high bar; it would exclude some true cases but would not misclassify the nature of the problem. A non-discriminating criterion is a different and more serious defect: it fails to separate the populations it is meant to separate in either direction, so no simple recalibration of the threshold can repair it. That distinction matters for the field’s response. Adjusting stringency would preserve a broken instrument; recognizing non-discrimination points toward rethinking how opportunity is assessed in the postpartum context — perhaps by evaluating opportunity at the level of uninterrupted sleep segments rather than total time in bed, or by incorporating longitudinal follow-up to see whether sleep disturbance persists once infant-related disruption subsides.

It is worth noting the form of the contribution itself. Huang and Shen’s piece is a letter to the editor, not an original data analysis; the authors state explicitly that no new data or materials were generated or analyzed, and that all cited evidence comes from already-published articles. Letters of this kind play an outsized role in sleep medicine, where diagnostic criteria are codified in manuals and revised slowly, and where a well-aimed critique of a single criterion clause can shape the agenda for the next revision cycle. The authors declare no competing interests and report no funding, and the letter moved quickly through editorial review — received on 18 September 2026, accepted on 23 September, and published on 1 October — suggesting the editors judged the argument timely in relation to the prospective postpartum study it addresses.

For clinicians and researchers, the takeaway is a call to treat the postpartum insomnia diagnosis with more nuance than the standard criteria currently support. For new parents, the message is equally important: fragmented sleep after childbirth sits on a spectrum that runs from entirely expected disruption to a treatable disorder, and the line between them is harder to draw than diagnostic manuals imply. As longitudinal cohorts such as the pregnancy-to-two-years study continue to mature, the evidence base for revising the opportunity criterion should grow. Until then, Huang and Shen’s letter stands as a concise warning that one of sleep medicine’s foundational diagnostic assumptions — that given the chance to sleep, insomniacs still cannot — simply does not translate to the nursery.

Subject of Research: Diagnostic validity of the adequate sleep opportunity criterion for postpartum insomnia disorder

Article Title: The “adequate sleep opportunity” criterion in postpartum insomnia: non-discriminating, not merely too strict

Article References: Huang, B., & Shen, Y. (2026). The “adequate sleep opportunity” criterion in postpartum insomnia: non-discriminating, not merely too strict. Journal of Clinical Sleep Medicine, 22(1), Article 175. https://doi.org/10.1007/s44470-026-00204-6

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00204-6

Keywords: postpartum insomnia, sleep opportunity criterion, insomnia disorder, diagnostic criteria, sleep medicine, perinatal mental health, sleep disruption, new mothers, cognitive behavioral therapy for insomnia, postnatal depression, Journal of Clinical Sleep Medicine, maternal sleep

The letter arrives as a direct response to an updated meta-analysis of randomized controlled trials of acceptance and commitment therapy for insomnia, published earlier in the same journal by Barroso and colleagues. That meta-analysis pooled trial data to estimate how well ACT performs against control conditions and other active treatments, and its findings have been interpreted by some as support for expanding ACT’s footprint in behavioral sleep medicine. Saripudin and Saputri do not dispute the underlying data. Instead, they use the meta-analysis as a springboard to ask a more fundamental question: are current trials of ACT for insomnia designed well enough to tell us where the therapy genuinely helps, for whom, and at what point in a treatment pathway it should be deployed?

Acceptance and commitment therapy differs from standard CBT-I in a philosophically and mechanically important way. Rather than targeting sleep directly through stimulus control, sleep restriction, and cognitive restructuring of dysfunctional beliefs about sleep, ACT draws on relational frame theory and psychological flexibility research, a framework codified by Steven Hayes and colleagues in their foundational 2006 model of the approach. In the insomnia context, this means helping patients observe their sleep-related thoughts and anxieties without struggling against them, defusing from catastrophic predictions about the consequences of a bad night, and redirecting energy toward valued activities regardless of how sleep unfolds. The metacognitive model of insomnia developed by Ong, Ulmer, and Manber in 2012 provides the theoretical scaffolding here: insomnia is maintained not simply by poor sleep but by excessive monitoring of sleep, worry about sleep, and futile efforts to control a largely involuntary process.

The first methodological challenge highlighted by the letter concerns the heterogeneity of what actually gets called ACT in insomnia trials. Component network meta-analysis of CBT for chronic insomnia, such as the 2024 systematic review by Furukawa and colleagues in JAMA Psychiatry, has shown that the specific ingredients bundled inside a treatment package matter, and that different delivery formats produce different effect sizes. When one trial delivers pure acceptance and defusion exercises while another folds in sleep restriction, relaxation training, and psychoeducation under the ACT banner, the pooled estimate from a meta-analysis becomes difficult to interpret. Saripudin and Saputri argue that future trials must specify and measure the treatment components with the same rigor applied to pharmacological dosing, otherwise clinicians cannot know whether it is the acceptance processes or the borrowed behavioral elements driving observed improvements.

A second challenge involves the measurement of the very mechanisms ACT claims to target. If psychological flexibility, acceptance, and defusion are the active ingredients, then trials should track changes in these processes and demonstrate that they mediate sleep outcomes. Many existing studies measure only symptom endpoints such as insomnia severity or sleep-onset latency, leaving a black box between intervention and effect. Without mediation analyses and process measures, the field cannot distinguish a genuine mechanism-driven therapy from a repackaged relaxation intervention. The letter’s authors contend that this measurement gap is not a technical detail but the central scientific question, because it determines whether ACT is a distinct therapeutic modality for insomnia or simply a sympathetic framing of existing techniques.

The third pillar of the letter is the proposal to integrate ACT into a stepped-care architecture for insomnia. Stepped-care models allocate treatment intensity according to severity and prior response, beginning with low-intensity, widely accessible interventions and escalating only when needed. In such a system, ACT could occupy a strategically valuable position: for patients who refuse or fail sleep restriction, for those whose insomnia is entangled with chronic pain, anxiety, or depression, and for individuals whose primary problem is the struggle against sleep rather than sleep itself, acceptance-based approaches may be more acceptable and more effective than classic CBT-I protocols. Positioning ACT as either a first-line option for struggle-dominant presentations or a second step after CBT-I nonresponse is, in the authors’ view, a testable and clinically meaningful hypothesis that current trial designs have not yet addressed.

Underpinning this stepped-care argument is the often-overlooked issue of acceptability. Research on adherence to CBT-I, including the systematic review by Matthews and colleagues published in Sleep Medicine Reviews, has documented that many patients abandon sleep restriction partway through, and studies of patient perceptions toward insomnia treatments by Cheung and colleagues have shown that people frequently hold reservations about behavioral prescriptions that initially worsen sleep. Acceptability, the letter argues, should be treated as a formal outcome metric rather than an afterthought. Trials should systematically quantify tolerability, dropout attributable to treatment burden, patient-rated willingness to continue, and the match between treatment demands and patient preferences. If ACT’s chief comparative advantage is that patients will actually do it, then the field needs standardized instruments to demonstrate that advantage rather than relying on anecdote.

The implications of the letter extend beyond behavioral sleep medicine into health policy and service design. Insomnia affects a substantial share of adults, contributes to accidents, cardiovascular and metabolic disease, and psychiatric morbidity, and consumes enormous healthcare resources, yet access to trained CBT-I therapists remains scarce in most health systems. Digital and guided self-help formats have been proposed to close the access gap, and the component questions raised by Saripudin and Saputri apply with equal force here: if ACT is delivered through an app or a brief primary-care consultation, which elements survive the compression, and do the acceptance processes still engage? The authors suggest that acceptability metrics become a gating criterion in stepped-care algorithms, allowing services to route patients toward the least intensive treatment they will actually complete, which maximizes population-level benefit from limited clinician time.

None of this diminishes the significance of the updated meta-analysis that prompted the correspondence. Pooling randomized controlled trials is exactly the right starting point, and the finding that ACT produces measurable benefits for insomnia patients is noteworthy on its own terms. The letter’s contribution is to insist on intellectual honesty about what the pooled estimate can and cannot support. Effect sizes derived from heterogeneous packages, without mechanism data, without acceptability measurement, and without head-to-head comparisons at defined steps of a care pathway, justify curiosity rather than clinical rollout. The distinction matters because premature scaling of an incompletely characterized therapy risks repeating the access-versus-evidence tensions that have complicated other behavioral health rollouts.

What happens next will depend on whether trialists take up the design challenges laid out in the letter. The prescriptions are concrete: pre-register component definitions, include validated process measures of psychological flexibility and acceptance, conduct formal mediation analyses, report standardized acceptability outcomes, and embed ACT within stepped-care trials that compare explicit treatment sequences rather than isolated packages. If the field responds, the result could be a genuinely personalized behavioral sleep medicine, in which a patient whose insomnia is driven by nocturnal struggle is steered toward acceptance-based work while a patient with entrenched sleep-incompatible habits receives restriction-based CBT-I first. If the field does not respond, acceptance and commitment therapy risks remaining an attractive but under-specified option, championed by enthusiasts and underused by systems. Saripudin and Saputri’s letter is, in effect, a roadmap for turning promising pooled statistics into a defensible, patient-centered treatment strategy, and it arrives at a moment when demand for better insomnia care has never been higher.

Subject of Research: Optimizing acceptance and commitment therapy for insomnia through improved trial methodology, stepped-care integration, and acceptability measurement

Article Title: Optimizing the role of acceptance and commitment therapy for insomnia: methodological challenges, stepped-care integration, and acceptability metrics

Article References: Saripudin, M., & Saputri, H. (2026). Optimizing the role of acceptance and commitment therapy for insomnia: methodological challenges, stepped-care integration, and acceptability metrics. Journal of Clinical Sleep Medicine, 22(1), Article 160. https://doi.org/10.1007/s44470-026-00184-7

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00184-7

Keywords: acceptance and commitment therapy, insomnia, cognitive behavioral therapy for insomnia, stepped care, psychological flexibility, sleep medicine, meta-analysis, treatment acceptability, randomized controlled trials, behavioral sleep medicine, adherence, methodology

The core of this scientific breakthrough focuses on the concept of cortical hyperarousal, a state where the brain remains in a high-frequency vigilance mode even during the deepest stages of non-rapid eye movement sleep. For an average person, the transition into sleep involves a rhythmic slowing of neural oscillations, characterized by delta waves and spindles that signal the body to begin its reparative functions. However, for those suffering from chronic insomnia, this process is frequently hijacked by high-frequency power, specifically in the beta and gamma ranges, which keeps the mind tethered to a wake-like state of alertness. Sforza and the research team meticulously tracked these high-frequency EEG disturbances, providing empirical evidence that the subjective experience of “tossing and turning” is actually rooted in an objective, measurable electrical thunderstorm occurring within the cortex. This hyperarousal serves as a constant barrier, preventing the brain from entering the truly restorative phases of sleep and leaving patients trapped in a metabolic state of high demand that drains their cognitive and emotional reserves. The study’s ability to map these patterns via polysomnography provides a rigorous scientific baseline for what was once considered a purely psychological or subjective complaint, effectively bridging the gap between clinical psychiatry and hard-core neurobiology.

What makes this specific multicentric study so viral and impactful is the revelation that CBT-I acts as a direct neurological intervention capable of silencing this hyperarousal. Unlike traditional sleeping pills which might force the brain into a state of unconsciousness without addressing the underlying electrical hyperactivity, the cognitive and behavioral strategies employed in this therapy appear to retrain the brain’s inhibitory mechanisms. The researchers observed a significant reduction in EEG power within the high-frequency bands following the intervention, suggesting that the therapy facilitates a more natural and profound transition into slow-wave sleep. This is not just about sleeping longer; it is about changing the quality of the neural environment itself so that the brain no longer feels the need to remain on high alert. By utilizing techniques such as sleep restriction, stimulus control, and cognitive restructuring, patients are essentially performing a form of neurological biofeedback that eventually manifests as a calmer, more synchronized EEG profile. This finding elevates CBT-I from a supplemental talk therapy to an essential neuro-modulatory tool that addresses the biological root causes of sleep disturbances, marking a major milestone in the evolution of sleep medicine.

The methodology employed by Sforza, Morin, and Dang-Vu was exceptionally rigorous, ensuring that their findings would stand up to the highest levels of scientific scrutiny within the psychiatric community. By coordinating across several centers, the study eliminated the localized biases that often plague smaller clinical trials, providing a diverse and comprehensive dataset of polysomnographic recordings. Each participant underwent detailed EEG monitoring before and after the CBT-I treatment, allowing the scientists to observe the granular shifts in spectral power across different frequency domains with pinpoint accuracy. The team focused specifically on the “power spectral analysis,” a sophisticated mathematical technique that breaks down sleep into its component frequencies, revealing the exact moments where the hyperarousal was most prevalent. Their results showed that the most significant improvements occurred in the reduction of fast-frequency activity during the critical early cycles of sleep, which are essential for metabolic recovery and memory consolidation. This level of technical detail provides a new blueprint for how sleep disorders should be diagnosed and treated, moving away from subjective sleep diaries toward objective, data-driven neurological assessments that prioritize the brain’s electrical health.

To understand why this discovery is resonating so strongly with both scientists and the public, one must consider the sheer scale of the global sleep crisis and the limitations of current pharmaceutical solutions. Many patients who rely on benzodiazepines or Z-drugs find that while they fall asleep faster, they often wake up feeling groggy or cognitively impaired because these drugs can disrupt the natural architecture of sleep stages. In contrast, the Sforza study shows that CBT-I restores the natural rhythm, decreasing the “micro-arousals” that fracture the sleep experience and lead to daytime fatigue. This study proves that a psychological intervention can achieve what chemical compounds often fail to do: create a sustainable, long-term reduction in the physiological markers of stress within the brain. The data suggests that by addressing the cognitive patterns and behaviors that feed the hyperarousal loop, patients are essentially teaching their nervous systems to relinquish the state of hyper-vigilance that characterizes insomnia. This is a game-changer for anyone who has felt that their mind simply “won’t turn off” at night, as it provides a clear, evidence-based pathway to regaining control over their own neurophysiology without the fear of dependency or side effects associated with medication.

Furthermore, the research delves into the fascinating interplay between the prefrontal cortex and the subcortical regions of the brain, suggesting that CBT-I strengthens the top-down regulation of arousal. During the sessions, patients learn to disconnect their beds from the stress of wakefulness, which physically alters the associative pathways in the brain that trigger the release of cortisol and adrenaline during the night. The EEG data captured in this study reflects this shift, showing a more stable and resilient transition into the deeper, slower oscillations of the delta range. This suggests that the therapy is not just a temporary fix but a permanent recalibration of the brain’s default settings. As the high-frequency beta activity diminishes, the brain’s “glymphatic system,” which clears out metabolic waste and toxins during sleep, can function more efficiently. This has profound implications for long-term brain health, potentially reducing the risk of neurodegenerative diseases that are exacerbated by chronic sleep deprivation. The study’s technical depth highlights that the benefits of CBT-I extend far beyond the bedroom, impacting the very hardware of our cognitive processing and emotional regulation.

The implications for the future of personalized medicine are staggering, as this research paves the way for “precision sleep therapy” based on a patient’s unique EEG fingerprint. By identifying the specific frequency bands that are overactive in a particular individual, clinicians may soon be able to tailor CBT-I protocols to target those exact electrical imbalances. Sforza’s team has demonstrated that the “multicentric” approach is the gold standard for this kind of research, as it accounts for the variability in human sleep patterns while still finding a universal therapeutic effect. This study acts as a clarion call for healthcare systems to prioritize behavioral medicine, proving that the mind and body are not separate entities but a single, integrated system where thoughts can physically alter the electrical currents of the brain. The viral nature of this discovery lies in its empowering message: we have the internal capacity to heal our own neurological circuits through guided behavior and cognitive change. This represents a victory for the human potential to self-regulate and provides a scientific foundation for a new era of sleep health that is grounded in the mastery of one’s own mental environment.

In the broader context of neurobiology, the reduction of sleep EEG hyperarousal through CBT-I suggests a high degree of neuroplasticity even in adults who have suffered from insomnia for decades. The brain is not a static organ; it is a dynamic, ever-changing landscape that responds to the inputs we provide it. When patients engage in the rigorous protocols of CBT-I, they are essentially providing a new set of environmental and psychological inputs that force the brain to adapt. The suppression of fast-frequency oscillations is evidence of this adaptation, reflecting a nervous system that has learned to feel safe and relaxed in the presence of the bed. This “de-conditioning” of the arousal response is what makes the therapy so effective in the long run, as it removes the trigger rather than just treating the symptom. The Sforza study provides the graphical and mathematical proof of this neuroplastic shift, making it impossible to ignore the physiological reality of psychological change. For the scientific community, this is a landmark moment that validates the use of non-invasive therapies as primary treatments for complex neurological conditions, setting a high bar for future research into human consciousness and health.

As we look deeper into the data presented by the researchers, the role of sleep spindles becomes a focal point of interest, as these bursts of neural activity are crucial for protecting sleep against external noise and internal interruptions. The multicentric study suggests that as hyperarousal decreases, the density and organization of sleep spindles may improve, further stabilizing the sleep state against the intrusion of wake-like brainwaves. This suggests a restorative synergy where the reduction of “bad” activity (high-frequency noise) allows the “good” activity (spindles and delta waves) to flourish. This delicate balance is what defines healthy sleep, and Sforza and his team have shown that CBT-I is the key to restoring this equilibrium. By focusing on the spectral power of the EEG, the study provides a high-resolution view of the brain’s struggle and eventual triumph over insomnia. It is a story of biological resilience, told through the language of voltages and frequencies, and it offers a beacon of hope for a world that is increasingly deprived of the rest it so desperately needs to function at its peak capacity.

The social and economic impact of these findings cannot be overstated, considering that insomnia costs the global economy billions of dollars in lost productivity and increased healthcare expenditures every year. By proving that a relatively short-term behavioral intervention can produce such profound and objectively measurable changes in brain activity, this research makes a compelling case for the widespread adoption of CBT-I as a first-line treatment in primary care. If we can treat the electrical roots of insomnia without expensive medications or invasive procedures, we can significantly improve the quality of life for a significant portion of the population. The viral appeal of this study is driven by its accessibility and its promise of a natural solution to a modern epidemic. As the word spreads through digital platforms and scientific journals alike, the “Sforza study” is becoming shorthand for the revolutionary idea that our brains can be retrained to find peace. This is the hallmark of modern science at its best: providing clear, actionable insights that translate complex data into a better life for people around the world, one restful night at a time.

Technically, the study utilized advanced signal processing algorithms to filter out artifacts and ensure that the EEG readings were a true reflection of cortical activity rather than muscle tension or eye movement. This level of precision is necessary when dealing with high-frequency bands like beta and gamma, which can often be obscured by the signals of the body. By isolating the cortical hyperarousal, the researchers were able to prove that the “racing mind” of the insomniac is not just a feeling but a specific electrical state within the gray matter of the brain. The study’s success in capturing this data across multiple sites confirms that these findings are robust and replicable, which is the gold standard for scientific discovery. The “multicentric polysomnographic” aspect of the research is particularly impressive, as it required a level of coordination and standardization that is rare in the field of sleep medicine. This collaborative effort has yielded a dataset that will likely be analyzed for years to come, providing further insights into the mechanisms of sleep, aural arousal, and the power of behavioral change.

One of the most profound takeaways from the work of Sforza, Morin, and Dang-Vu is the realization that the brain’s vigilance system is highly sensitive to the narratives we tell ourselves about our sleep. Through cognitive restructuring, CBT-I disrupts the catastrophic thinking that often accompanies a night of poor sleep, which in turn cools down the amygdala’s influence over the cortex. This reduction in emotional salience is mirrored in the EEG data as a decrease in the power of frequencies associated with anxiety and alertness. Consequently, the brain is no longer “scanning for threats” in the middle of the night, allowing the natural homeostatic drive for sleep to take over. This study beautifully illustrates how a change in thought can lead to a change in frequency, transforming the brain from a state of high-resistance vigilance to one of receptive, deep restoration. It is a powerful reminder that our mental health and our physical health are inextricably linked, and that the most effective treatments are those that address the human being as a whole, integrated organism capable of remarkable self-correction.

Ultimately, the publication of this study in 2026 marks the beginning of a new era in neuroscience where the effects of psychotherapy are measured with the same precision as surgical or pharmacological interventions. The effectiveness of Cognitive behavioral therapy for insomnia on sleep EEG hyperarousal is not just a title; it is a statement of fact that has been verified through the most rigorous scientific methods available today. As we move forward, this research will undoubtedly inspire a new generation of sleep scientists to explore the nuances of the sleeping brain and the myriad ways we can support its health through behavioral and environmental modifications. The viral success of this story is a testament to our universal quest for rest and the deep satisfaction that comes from finally understanding the “why” behind our restless nights. With the data provided by Sforza and his colleagues, we now have a roadmap to a quieter, calmer brain, ensuring that the technology of our minds remains our greatest asset rather than a source of sleepless distress. The era of the hyperaroused brain is ending, and the era of restorative, scientifically-proven rest is finally here.

As the scientific community continues to digest the implications of this multicentric polysomnographic study, the conversation is shifting toward how these neurological changes can be sustained over a lifetime. The study suggests that the “quieting” of the EEG hyperarousal observed after CBT-I is not merely a transient effect but a fundamental shift in the brain’s processing of sleep-wake states. This suggests that the skills learned during the therapy—such as managing the relationship between the bed and the act of sleeping—become hardwired into the brain’s operational pathways. This longitudinal perspective is crucial because it highlights the superiority of behavioral interventions over chemical ones, which often see a relapse of symptoms once the drug is discontinued. By focusing on the EEG power spectrum, the researchers have provided the world with a visual and mathematical confirmation of healing, proving that the human brain can indeed learn its way out of the prison of chronic insomnia, leading to a future where deep, uninterrupted sleep is accessible to everyone, regardless of their past struggles.

Subject of Research: The impact of Cognitive Behavioral Therapy for Insomnia (CBT-I) on cortical hyperarousal as measured by EEG and polysomnography in patients with chronic insomnia.

Article Title: The effectiveness of Cognitive behavioral therapy for insomnia on sleep EEG hyperarousal: a multicentric polysomnographic study.

Article References:

Sforza, M., Morin, C.M., Dang-Vu, T.T. et al. The effectiveness of Cognitive behavioral therapy for insomnia on sleep EEG hyperarousal: a multicentric polysomnographic study.
Transl Psychiatry (2026). https://doi.org/10.1038/s41398-026-03882-1

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41398-026-03882-1

Keywords: Insomnia, CBT-I, Sleep EEG, Hyperarousal, Polysomnography, Neuroplasticity, Spectral Analysis, Translational Psychiatry, Cortical Arousal, Sleep Medicine.

Insomnia and depression frequently co-occur, creating a formidable challenge for clinical treatment and cognitive recovery. Both conditions are known to exert a heavy toll on cognitive faculties, including attention, working memory, and executive functioning. While CBT-I has been well-documented to improve subjective perceptions of cognition, less is known about its capacity to effect measurable improvements in actual cognitive function across these populations. The recent study seeks to fill this knowledge gap by employing robust objective measures to assess cognitive changes following CBT-I intervention.

This investigation recruited 170 participants drawn from two randomized clinical trials, including patients exclusively experiencing insomnia and those with combined insomnia and depression. These individuals underwent structured 9 to 12-week internet-delivered CBT-I programs, designed to address dysfunctional sleep habits and cognitive distortions associated with insomnia symptoms. The trial’s innovative approach lies in its integration of cognitive assessments derived from the CANTAB battery, a computerized collection of neuropsychological tests renowned for their sensitivity and reliability in detecting subtle changes in cognitive performance.

Pre- and post-treatment cognitive outcomes were meticulously evaluated across parameters measuring sustained attention, working memory, executive planning, and emotional processing. Analytical methods centered on linear regression and mixed-effects modeling permitted nuanced dissecting of the data, accounting for interindividual variability and enabling robust determination of therapy effects. The results illuminated several domains where CBT-I exerted significant positive impacts, reflecting measurable cognitive improvements in the participant group at large.

Among the most notable findings were enhancements in performance on the Rapid Visual Processing task, an indicator of sustained attention and vigilance. Post-treatment data revealed statistically significant increases in correct detections and reductions in missed targets, coupled with a modest decrease in response latency. These markers collectively suggest that CBT-I not only alleviates subjective sleep difficulties but also translates into sharper sustained attention, laying a foundation for broader cognitive restoration.

Further gains emerged in executive function as demonstrated by improved problem-solving accuracy on the Stockings of Cambridge task. Patients displayed enhanced ability to plan and execute complex sequences of moves, reflecting a revitalization in executive control domains critical for adaptive daily functioning. Emotional processing, measured through the Affective Go/No-Go paradigm, also showed gains, with reduced commission errors and affective bias, suggesting CBT-I fosters improved regulation of emotional responses, an essential asset for mental health resilience.

Interestingly, the presence of comorbid depression did not broadly predict diminished cognitive outcomes across most tasks, indicating that insomnia’s cognitive repercussions might be somewhat independent of concurrent mood disturbances. However, a more nuanced deficit was observed in spatial working memory among depressed individuals, evidenced by shorter span length, fewer successful attempts, and prolonged latency on the Spatial Span task. This suggests that depression selectively impairs certain memory circuits, underscoring the complexity of cognitive impairments in co-occurring disorders.

Despite these encouraging improvements, the study found no straightforward associations between the degree of symptom reduction in insomnia or depression and changes in cognitive scores. This dissociation invites further inquiry into the mechanistic pathways through which cognitive enhancements transpire and indicates multifaceted factors beyond symptom alleviation drive neurocognitive recovery. It also accentuates the necessity of longitudinal follow-ups to map the trajectory and sustainability of cognitive gains post-CBT-I.

Methodologically, this study sets a precedent by integrating internet-delivered interventions with rigorous objective cognitive assessments, advancing the feasibility of large-scale cognitive rehabilitation programs. Nevertheless, the authors acknowledge requisite refinements such as controlling for practice effects inherent in repeated cognitive testing and exploring the durability of cognitive benefits over extended timeframes. Such improvements will fortify the evidentiary framework needed to optimize CBT-I protocols tailored for cognitive enhancement.

The implications of these findings bear significant weight for clinical practice and mental health policy. By demonstrating tangible cognitive improvements via CBT-I, clinicians can advocate for early, accessible, and evidence-based behavioral treatments that transcend mere symptom management. Enhanced cognitive function translates into better occupational performance, social engagement, and overall quality of life, particularly for individuals navigating the dual burden of insomnia and depression.

This study also sparks a broader conversation about the neurobiological underpinnings linking sleep, mood regulation, and cognition. The partial independence of cognitive deficits from mood symptom severity challenges simplistic models and encourages interdisciplinary research integrating neuroimaging, neurochemical assays, and behavioral paradigms. Such endeavors promise to unravel the complex circuitry affected by these intertwined disorders, ultimately informing targeted pharmacological and psychotherapeutic interventions.

In conclusion, while the cognitive impairments observed in insomnia with comorbid depression are subtle, the efficacy of CBT-I in enhancing attention, working memory, executive function, and emotional processing emerges as a beacon of hope. The research illuminates a pathway towards objective cognitive recovery, emphasizing that sleep-focused behavioral therapy holds promise beyond symptom relief, extending into domains vital for holistic brain health. As research progresses, the integration of cognitive metrics into clinical workflows will enhance precision treatment and redefine recovery benchmarks.

The journey toward elucidating the full potential of CBT-I in cognitive amelioration is ongoing, and this study marks a pivotal step forward. Future investigations must embrace larger cohorts, more diverse populations, and multimodal assessment strategies to fully characterize the cognitive trajectories of individuals grappling with insomnia and depression. Harnessing these insights will empower clinicians and researchers alike to devise innovative, personalized solutions that restore not only restful sleep but also the cognitive vitality that underpins human thriving.

Subject of Research: Cognitive function in insomnia patients with and without comorbid depression treated with cognitive behavioral therapy for insomnia.

Article Title: Objectively measured cognitive function in insomnia patients with and without comorbid depression treated with cognitive behavioral therapy for insomnia.

Article References:
Tamm, S., Jernelöv, S., Forsell, E. et al. Objectively measured cognitive function in insomnia patients with and without comorbid depression treated with cognitive behavioral therapy for insomnia. BMC Psychiatry 25, 916 (2025). https://doi.org/10.1186/s12888-025-07460-5

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12888-025-07460-5

Insomnia is a common and often underappreciated complication for cancer survivors, reported to affect a majority at some point during or after treatment. Despite its prevalence, many therapeutic approaches have yielded inconsistent results, thereby necessitating a rigorous evaluation of existing interventions. The study conducted by Cooper et al. exhaustively reviewed 19 RCTs involving 1,803 participants, predominantly women with breast cancer and a mean age of 55, to ascertain the magnitude of CBT-I’s benefits.

The methodology harnessed for this review aligned with gold-standard protocols, including adherence to the Cochrane Handbook recommendations and PRISMA guidelines. These frameworks ensure meticulous assessment of evidence quality and minimize bias. Searches spanned eight major databases, capturing well-designed studies where adult cancer survivors with clinically significant insomnia were randomized into CBT-I or various control conditions like usual care, wait-lists, or sleep hygiene education.

The primary measure utilized to evaluate insomnia severity was the Insomnia Severity Index (ISI), administered at the conclusion of interventions. Secondary outcomes examined sleep diary metrics, fatigue levels, and health-related quality of life (HRQL), recognizing that insomnia’s impact extends beyond mere sleep duration or quality. Statistical analyses focused on between-group mean differences and standardized mean differences, with the incorporation of minimal clinically important difference (MCID) thresholds guided by authoritative bodies such as the American College of Physicians.

Results present a nuanced view. While CBT-I demonstrated significant improvements in ISI scores compared to controls—averaging a reduction of 4.4 points—the improvements fell short of the 6-point MCID threshold conventionally regarded as representing clinically important benefit for "many" patients. However, these effects exceeded half of the minimal important change (MIC), indicating that a substantial cohort of cancer survivors likely experienced meaningful relief. This distinction emphasizes that the clinical relevance of CBT-I may be more modest but still appreciable in this demographic.

Further analyses on subjective measures such as sleep diary parameters—including sleep latency, wake after sleep onset, and sleep efficiency—also favored CBT-I, alongside noted improvements in fatigue and HRQL scores. Yet, these gains did not reach consistency or magnitude sufficient to surpass established clinical significance thresholds. This pattern underscores the complexity of insomnia’s etiology and resistance in cancer survivors, suggesting that CBT-I may benefit individual patients variably rather than uniformly.

One intriguing finding from subgroup analyses was the lack of modification of treatment effects based on intervention characteristics or cancer-related variables. This uniformity across diverse participant profiles strengthens the generalizability of the results but also signals the need for tailored therapeutic approaches to enhance efficacy among non-responders.

However, the certainty of evidence was rated as low to very low, primarily due to heterogeneity among studies and potential biases such as publication bias, performance bias, and selective reporting. Such limitations highlight the challenges inherent in insomnia research amid cancer survivorship, including variability in intervention delivery, adherence, and outcome measurement.

The implications for clinical practice are substantial. Although CBT-I remains a cornerstone of insomnia management given its safety profile and non-pharmacologic nature, the modest average effect sizes observed call for augmented or complementary strategies. There is a pressing need to identify factors predictive of response and to innovate interventions that can effectively address persistent insomnia in a significant subset of cancer survivors.

This study also redirects focus toward the qualitative burden of insomnia, emphasizing patient-centered perspectives on what constitutes meaningful improvement. The differentiation between population-level statistical significance and individual clinical benefit is vital for guiding shared decision-making between clinicians and patients navigating post-cancer care.

Moreover, ongoing research should aim to dissect the biopsychosocial mechanisms underlying refractory insomnia and evaluate novel, integrative approaches—possibly blending behavioral therapy with pharmacological or technological adjuncts. Tailoring CBT-I content to the unique challenges faced by cancer survivors, such as treatment side effects and psychological sequelae, may also amplify therapeutic gains.

As survivorship increases globally, optimizing supportive care interventions like CBT-I gains even greater urgency. This systematic review contributes a rigorous benchmark for future trials, challenging researchers to elevate methodological standards and to incorporate patient-reported outcomes that reflect real-world impact.

In conclusion, cognitive-behavioral therapy for insomnia offers discernible but limited clinical benefit for cancer survivors. While many experience appreciable symptom relief, the therapy does not universally meet thresholds indicating that "many" patients benefit substantially. The findings advocate for the development of enhanced insomnia therapies and tailored interventions aimed at the diverse needs of cancer survivors, ensuring that sleep disturbances do not compromise their quality of life after cancer treatment.

This comprehensive meta-analysis not only enriches our understanding of insomnia management in oncology settings but also exemplifies the critical importance of precise effect measurement and evidence synthesis in translating research into meaningful care improvements.

Subject of Research: Effects of cognitive-behavioral therapy for insomnia (CBT-I) among cancer survivors

Article Title: Effects of cognitive-behavioral therapy for insomnia compared with controls among cancer survivors: a systematic review and meta-analysis of randomized trials

Article References:
Cooper, J.T., Svoboda, E., Prochazka, A.V. et al. Effects of cognitive-behavioral therapy for insomnia compared with controls among cancer survivors: a systematic review and meta-analysis of randomized trials. BMC Cancer 25, 871 (2025). https://doi.org/10.1186/s12885-025-14192-y

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14192-y